160 related articles for article (PubMed ID: 28916659)
1. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance.
Chen F; Xu G; Qin X; Jin X; Gou S
J Pharmacol Exp Ther; 2017 Nov; 363(2):221-239. PubMed ID: 28916659
[TBL] [Abstract][Full Text] [Related]
2. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
3. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments.
Wang Y; Wang X; Xu G; Gou S
J Med Chem; 2021 Apr; 64(7):4163-4178. PubMed ID: 33784109
[TBL] [Abstract][Full Text] [Related]
4. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
5. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
Qin X; Fang L; Chen F; Gou S
Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717
[TBL] [Abstract][Full Text] [Related]
6. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
7. A Pt(IV)-based mononitro-naphthalimide conjugate with minimized side-effects targeting DNA damage response via a dual-DNA-damage approach to overcome cisplatin resistance.
Li Y; Yue K; Li L; Niu J; Liu H; Ma J; Xie S
Bioorg Chem; 2020 Aug; 101():104011. PubMed ID: 32599363
[TBL] [Abstract][Full Text] [Related]
8. Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair.
Chen F; Sun S; Liu N; Pei S; Zhu Q; Wang X; Gou S
Anticancer Drugs; 2019 Sep; 30(8):774-783. PubMed ID: 31274516
[TBL] [Abstract][Full Text] [Related]
9. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
Wang X; Li L; Pei S; Zhu Q; Chen F
Pharmazie; 2020 Mar; 75(2):94-101. PubMed ID: 32213241
[TBL] [Abstract][Full Text] [Related]
10. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
11. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.
Huang X; Huang R; Gou S; Wang Z; Liao Z; Wang H
Bioorg Med Chem; 2017 Sep; 25(17):4686-4700. PubMed ID: 28728896
[TBL] [Abstract][Full Text] [Related]
12. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
13. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
15. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
16. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
17. Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress.
Boldogh I; Roy G; Lee MS; Bacsi A; Hazra TK; Bhakat KK; Das GC; Mitra S
Toxicology; 2003 Nov; 193(1-2):137-52. PubMed ID: 14599773
[TBL] [Abstract][Full Text] [Related]
18. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
Fang L; Qin X; Zhao J; Gou S
Inorg Chem; 2019 Feb; 58(3):2191-2200. PubMed ID: 30657321
[TBL] [Abstract][Full Text] [Related]
19. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
Li L; Huang X; Huang R; Gou S; Wang Z; Wang H
Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977
[TBL] [Abstract][Full Text] [Related]
20. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
Tacconi EM; Badie S; De Gregoriis G; Reisländer T; Lai X; Porru M; Folio C; Moore J; Kopp A; Baguña Torres J; Sneddon D; Green M; Dedic S; Lee JW; Batra AS; Rueda OM; Bruna A; Leonetti C; Caldas C; Cornelissen B; Brino L; Ryan A; Biroccio A; Tarsounas M
EMBO Mol Med; 2019 Jul; 11(7):e9982. PubMed ID: 31273933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
